MCM
OMED

Mazama Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Mazama Capital Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,528
Closed -$51K – 314
2014
Q1 		$51K Sell
1,528
-2,342
-61% -$78.9K 0.05% 141
2013
Q4 		$114K Buy
3,870
+1,824
+89% +$33.4K 0.06% 144
2013
Q3 		$31K Buy
+2,046
New +$37.9K 0.02% 185

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Mazama Capital Management's OMED Position: Q2 2014 in Review

Mazama Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2014, closing a stake of 1,528 shares — an estimated $51K sold.

Mazama Capital Management first reported a position in OMED in Q3 2013 and held it in 3 quarters. The position peaked at $114K in Q4 2013. 63 funds tracked by Wall St. Rank hold OMED as of Q2 2014.

  • Mazama Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Mazama Capital Management sold 1,528 OncoMed Pharmaceuticals, Inc. shares in Q2 2014, an estimated $51K.
  • Mazama Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 3 quarters.
  • Mazama Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $114K in Q4 2013.
  • 63 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2014.

Based on Mazama Capital Management's 13F filing for Q2 2014, filed 28 Jul 2014.